… ProQR Announces Second Quarter 2020 Operating and Financial … & CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We have continued to enroll patients in trials for …
Reported positive interim analysis findings from Phase 1/2 Stellar trial of QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa – study ongoing with dose expansion and escalation planned;Updated data from the Phase 1/2 InSight extension st